Regulation of allergic inflammatory responses by inhibitory receptors
D. Shik,
A. Munitz,
D. Shik
Department of Microbiology and Human Immunology, The Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel
Search for more papers by this authorA. Munitz
Department of Microbiology and Human Immunology, The Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel
Search for more papers by this authorD. Shik,
A. Munitz,
D. Shik
Department of Microbiology and Human Immunology, The Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel
Search for more papers by this authorA. Munitz
Department of Microbiology and Human Immunology, The Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel
Search for more papers by this authorCorrespondence:
A. Munitz, Department of Microbiology and Clinical Immunology, The Sackler School of Medicine, Tel-Aviv University, Ramat-Aviv, Tel-Aviv 69978, Israel. E-mail: [email protected]
Summary
An intricate network of activation and inhibitory signals tightly regulates immune responses. To date, multiple activation receptors have been described. These include receptors that mediate cellular functions such as adhesion, chemotaxis, cytokine signalling, mediator release, survival and phagocytosis. In contrast to these activation pathways, an opposing and suppressive receptor system has evolved. These receptors can override the signals elicited by the activation pathways and are broadly termed inhibitory receptors. Inhibitory receptors share unique intracellular signalling motifs and have key roles in various cellular and pathological conditions. Therefore, such receptors are potential targets for future therapeutics. In this review, we will discuss the structure and function of inhibitory receptors. In particular, we will focus on the expression and function of inhibitory receptors on mast cells and eosinophils and illustrate strategies for their inhibition in the settings of allergic inflammation.
Cite this as: D. Shik and A. Munitz, Clinical & Experimental Allergy, 2010 (40) 700–709.
References
- 1 Ravetch JV, Lanier LL. Immune inhibitory receptors. Science 290: 84–9.
- 2 Daeron M, Jaeger S, Du Pasquier L, Vivier E. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol Rev 2008; 224: 11–43.
- 3 Cooper MD. Inhibition of immune cell function. Immunol Rev 2008; 224: 11–43.
- 4 Lanier LL. NK cell receptors. Annu Rev Immunol 1998; 16: 359–93.
- 5 Munitz A. Inhibitory receptors on myeloid cells: new targets for therapy? Pharmacol Ther 2010; 125: 128–37.
- 6 Robinson MJ, Sancho D, Slack EC, LeibundGut-Landmann S, Reis e Sousa C. Myeloid C-type lectins in innate immunity. Nat Immunol 2006; 7: 1258–65.
- 7 Cella M, Dohring C, Samaridis J et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 1997; 185: 1743–51.
- 8 Meyaard L, Adema GJ, Chang C et al. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 1997; 7: 283–90.
- 9 Katz HR. Inhibition of pathologic inflammation by leukocyte Ig-like receptor B4 and related inhibitory receptors. Immunol Rev 2007; 217: 222–30.
- 10 Clark GJ, Ju X, Tate C, Hart DN. The CD300 family of molecules are evolutionarily significant regulators of leukocyte functions. Trends Immunol 2009; 30: 209–17.
- 11 Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev 2007; 7: 255–66.
- 12 Kanazawa N, Tashiro K, Miyachi Y. Signaling and immune regulatory role of the dendritic cell immunoreceptor (DCIR) family lectins: DCIR, DCAR, dectin-2 and BDCA-2. Immunobiology 2004; 209: 179–90.
- 13 Brooks AG, Posch PE, Scorzelli CJ, Borrego F, Coligan JE. NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J Exp Med 1997; 185: 795–800.
- 14 Held W, Cado D, Raulet DH. Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection. J Exp Med 1996; 184: 2037–41.
- 15 Chen CH, Floyd H, Olson NE et al. Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production. Blood 2006; 107: 1459–67.
- 16 Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev 2009; 9: 465–79.
- 17 Den Dunnen J, Gringhuis SI, Geijtenbeek TB. Innate signaling by the C-type lectin DC-SIGN dictates immune responses. Cancer Immunol Immunother 2009; 58: 1149–57.
- 18 Long EO. Regulation of immune responses through inhibitory receptors. Ann Rev Immunol 1999; 17: 875–904.
- 19 Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev 2008; 224: 70–84.
- 20 Fong DC, Malbec O, Arock M, Cambier JC, Fridman WH, Daeron M. Selective in vivo recruitment of the phosphatidylinositol phosphatase SHIP by phosphorylated Fc gammaRIIB during negative regulation of IgE-dependent mouse mast cell activation. Immunol Lett 1996; 54: 83–91.
- 21 Lu-Kuo JM, Joyal DM, Austen KF, Katz HR. gp49B1 inhibits IgE-initiated mast cell activation through both immunoreceptor tyrosine-based inhibitory motifs, recruitment of src homology 2 domain-containing phosphatase-1, and suppression of early and late calcium mobilization. J Biol Chem 1999; 274: 5791–6.
- 22 Katz HR. Inhibitory receptors and allergy. Curr Opin Immunol 2002; 14: 698–704.
- 23 Lu W, Gong D, Bar-Sagi D, Cole PA. Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol Cell 2001; 8: 759–69.
- 24 Zhang Z, Shen K, Lu W, Cole PA. The role of C-terminal tyrosine phosphorylation in the regulation of SHP-1 explored via expressed protein ligation. J Biol Chem 2003; 278: 4688–74.
- 25 Verbrugge A, Rijkers ES, De Ruiter T, Meyaard L. Leukocyte- associated Ig-like receptor-1 has SH2 domain-containing phosphatase-independent function and recruits C-terminal Src kinase. Eur J Immunol 2006; 36: 190–8.
- 26 Sayos J, Martinez-Barriocanal A, Kitzig F, Bellon T, Lopez-Botet M. Recruitment of C-terminal Src kinase by the leukocyte inhibitory receptor CD85j. Biochem Biophys Res Comm 2004; 324: 640–7.
- 27 Berg KL, Siminovitch KA, Stanley ER. SHP-1 regulation of p62(DOK) tyrosine phosphorylation in macrophages. J Biol Chem 1999; 274: 35855–65.
- 28 Robson JD, Davidson D, Veillette A. Inhibition of the Jun N-terminal protein kinase pathway by SHIP-1, a lipid phosphatase that interacts with the adaptor molecule Dok-3. Mol Cell Biol 2004; 24: 2332–43.
- 29 Zhang S, Phillips JH. Identification of tyrosine residues crucial for CD200R-mediated inhibition of mast cell activation. J Leukocyte Biol 2006; 79: 363–8.
- 30 Dietrich J, Nakajima H, Colonna M. Human inhibitory and activating Ig-like receptors which modulate the function of myeloid cells. Microbes Infect/Institut Pasteur 2000; 2: 323–9.
- 31 Kong XN, Yan HX, Chen L et al. LPS-induced down-regulation of signal regulatory protein {alpha} contributes to innate immune activation in macrophages. J Exp Med 2007; 204: 2719–31.
- 32 Sinclair NR. Why so many coinhibitory receptors? Scand J Immunol 1999; 50: 10–3.
- 33 Munitz A, McBride ML, Bernstein JS, Rothenberg ME. A dual activation and inhibition role for the paired immunoglobulin-like receptor B in eosinophils. Blood 2008; 111: 5694–703.
- 34 Nakayama M, Underhill DM, Petersen TW et al. Paired Ig-like receptors bind to bacteria and shape TLR-mediated cytokine production. J Immunol 2007; 178: 4250–9.
- 35 Pereira S, Zhang H, Takai T, Lowell CA. The inhibitory receptor PIR-B negatively regulates neutrophil and macrophage integrin signaling. J Immunol 2004; 173: 5757–65.
- 36 Zhang H, Meng F, Chu CL, Takai T, Lowell CA. The Src family kinases HcK and Fgr negatively regulate neutrophil and dendritic cell chemokine signaling via PIR-B. Immunity 2005; 22: 235–46.
- 37 Zhou JS, Friend DS, Feldweg AM et al. Prevention of lipopolysaccharide-induced microangiopathy by gp49B1: evidence for an important role for gp49B1 expression on neutrophils. J Exp Med 2003; 198: 1243–51.
- 38 Brown EJ. Leukocyte migration: dismantling inhibition. Trends Cell Biol 2005; 15: 393–5.
- 39 Takai T. Paired immunoglobulin-like receptors and their MHC class I recognition. Immunology 2005; 155: 433–40.
- 40 Ujike A, Takeda K, Nakamura A, Ebihara S, Akiyama K, Takai T. Impaired dendritic cell maturation and increased Th2 responses in PIR-B(−/−) mice. Nat Immunol 2002; 3: 542–8.
- 41 Kubagawa H, Burrows PD, Cooper MD. A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells. Proc Natl Acad Sci USA 1997; 94: 5261–6.
- 42 Maeda A, Kurosaki M, Ono M, Takai T, Kurosaki T. Requirement of SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 for paired immunoglobulin-like receptor B (PIR-B)-mediated inhibitory signal. J Exp Med 1998; 187: 1355–60.
- 43 Norris HH, Peterson ME, Stebbins CC et al. Inhibitory receptor gp49B regulates eosinophil infiltration during allergic inflammation. J Leukocyt Biol 2007; 82: 1531–41.
- 44 Boyce JA, Broide D, Matsumoto K, Bochner BS. Advances in mechanisms of asthma, allergy and immunology in 2008. J Allergy Clin Immunol 2009; 123: 569–74.
- 45 Munitz A, Levi-Schaffer F. Inhibitory receptors on eosinophil: a direct hit to a possible Achilles heel? J Allergy Clin Immunol 2007; 119: 1382–7.
- 46 Karra L, Berent-Maoz B, Ben-Zimra M, Levi-Schaffer F. Are we ready to downregulate mast cells? Curr Opin Immunol 2009; 21: 708–14.
- 47 Jacobsen EA, Taranova AG, Lee NA, Lee JJ. Eosinophils: singularly destructive effector cells or purveyors of immunoregulation? J Allergy Clin Immunol 2007; 119: 1313–20.
- 48 Wong MX, Roberts D, Bartley PA, Jackson DE. Absence of platelet endothelial cell adhesion molecule-1 (CD31) leads to increased severity of local and systemic IgE-mediated anaphylaxis and modulation of mast cell activation. J Immunol 2002; 168: 6455–62.
- 49 Bachelet I, Munitz A, Moretta A, Moretta L, Levi-Schaffer F. The inhibitory receptor Irp60 (CD300a) is expressed and functional on human mast cells. J Immunol 2005; 175: 7989–95.
- 50 Castells MC, Klickstein LB, Hassani K et al. gp49B1-alpha9(v)beta3 interaction inhibits antigen-induced mast cell activation. Nat Immunol 2001; 2: 436–42.
- 51 Masuda A, Nakamura A, Maeda T, Sakamoto Y, Takai T. Cis binding between inhibitory receptors and MHC class I can regulate mast cell activation. J Exp Med 2007; 204: 907–20.
- 52 Yokoi H, Choi OH, Hubbard W et al. Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. J Allergy Clin Immunol 2008; 121: 499–505, e1.
- 53 Katz HR. Inhibition of anaphylactic inflammation by the gp49B1 receptor on mast cells. Mol Immunol 2002; 38: 1301–5.
- 54 Malbec O, Fridman WH, Daeron M. Negative regulation of c-kit-mediated cell proliferation by Fc gamma RIIB. J Immunol 1999; 162: 4424–9.
- 55 Feldweg AM, Friend DS, Zhou JS et al. gp49B1 suppresses stem cell factor-induced mast cell activation secretion and attendant inflammation in vivo. Eur J Immunol 2003; 33: 2262–8.
- 56 Bachelet I, Munitz A, Berent-Maoz B, Mankuta D, Levi-Schaffer F. Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a. J Immunol 2008; 180: 6064–9.
- 57 Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol 2008; 9: 1215–23.
- 58 Maurer M, Echtenacher B, Hultner L et al. The c-kit ligand, stem cell factor, can enhance innate immunity through effects on mast cells. J Exp Med 1998; 188: 2343–8.
- 59 Prodeus AP, Zhou X, Maurer M, Galli SJ, Carroll MC. Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature 1997; 390: 172–5.
- 60 Kulka M., Alexopoulou L, Flavell RA, Metcalfe DD. Activation of mast cells by double-stranded RNA: evidence for activation through toll-like receptor 3. J Allergy Clin Immunol 2004; 114: 174–82.
- 61 Matsushima H, Yamada N, Matsue H, Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol 2004; 173: 531–41.
- 62 Supajatura V, Ushio H, Nakao A, Okumura K, Ra C, Ogawa H. Protective roles of mast cells against enterobacterial infection are mediated by toll-like receptor 4. J Immunol 2001; 167: 2250–6.
- 63 Sun J, Sukhova GK, Wolters PJ et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 2007; 13: 719–24.
- 64 Kubo T, Uchida Y, Watanabe Y et al. Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. J Exp Med 2009; 206: 1971–82.
- 65 Floyd H, Ni J, Cornish AL et al. Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily. J Biol Chem 2000; 275: 861–6.
- 66 Kikly KK, Bochner BS, Freeman SD et al. Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils. J Allergy Clin Immunol 2000; 105: 1093–100.
- 67 Von Gunten S, Vogel M, Schaub A et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol 2007; 119: 1005–11.
- 68 Nutku E, Aizawa A, Hudson SA, Bochner BS. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003; 101: 5014–20.
- 69 Nutku E, Hudson SA, Bochner BS. Mechanisms of Siglec-8-induced human eosinophil apoptosis: role of caspases and mitochondrial injury. Biochem Biophys Res Commun 2005; 336: 918–24.
- 70 Nutku-Bilir E, Hudson SA, Bochner BS. Interkeukin-5 priming of human eosinophils alters siglec-8 mediated apoptosis pathways. Am J Respir Cell Mol Biol 2008; 38: 121–4.
- 71 Hudson SA, Bovin NV, Schnaar RL, Crocker PR, Bochner BS. Eosinophil-selective binding and proapoptotic effect in vitro of a synthetic Siglec-8 ligand, polymeric 6′-sulfated sialyl Lewis x. J Pharmacol Exp Ther 2009; 330: 608–12.
- 72 Song DJ, Cho JY, Lee SY et al. Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling. J Immunol 2009; 183: 5333–41.
- 73 Zimmermann N, McBride ML, Yamada Y et al. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy 2008; 63: 1156–63.
- 74 Von Gunten S, Yousefi S, Seitz M et al. Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood 2005; 106: 1423–31.
- 75 Munitz A, Bachelet I, Eliashar R, Moretta A, Moretta L, Levi-Schaffer F. The inhibitory receptor Irp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. Blood 2006; 107: 1996–2003.
- 76 Kumar V, McNerney ME. A new self: MHC-class-I-independent natural killer cell self tolerance. Nat Rev Immunol 2005; 5: 363–74.
- 77 Eissmann P, Beauchamp L, Wooters J, Tilton JC, Long EO, Watzl C. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood 2005; 105: 4722–9.
- 78 El-Shazly A, Yamaguchi N, Masuyama K, Suda T, Ishikawa T. Novel association of the src family kinases, hck and c-fgr, with CCR3 receptor stimulation. A possible mechanisms for eotaxin-induced human eosinophil chemotaxis. Biochem Biophys Res Commun 1999; 264: 163–70.
- 79 Fulkerson PC, Zimmermann N, Brandt EB et al. Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-gamma (Mig, CXCL9). Proc Natl Acad Sci USA 2004; 101: 1987–92.
- 80 Fulkerson PC, Zhu H, Williams DA, Zimmermann N, Rothenberg ME. CXCL9 inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism. Blood 2005; 106: 436–43.
- 81 Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med 2002; 8: 518–21.
- 82 Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005; 11: 446–9.
- 83 Bachelet I, Munitz A, Levi-Schaffer F. Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. J Allergy Clin Immunol 2006; 117: 1314–20.
- 84 Munitz A, Bachelet I, Levi-Schaffer F. Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a. J Allergy Clin Immunol 2006; 118: 1082–9.
- 85 Tam SW, Demissie S, Thomas D, Daeron M. A bispecific antibody against human IgE and human FcgammaRII that inhibits antigen-induced histamine release by human mast cells and basophils. Allergy 2004; 59: 772–80.
- 86 Song DJ, Cho JY, Miller M et al. Anti-siglec-F antibody inhibits oral egg allergen induced intestinal eosinophilic inflammation in a mouse model. Clin Immunol 2009; 131: 157–69.
Citing Literature
